• Hepatic sEH Regulates Osteoclastogenesis via Nrf2 in Osteopo

  2026-05-28

  A recent study uncovers a liver-bone signaling axis in osteoporosis, showing that hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing Nrf2-mediated antioxidant responses. These findings highlight the therapeutic potential of sEH inhibitors for modulating bone resorption through redox and fatty acid epoxide pathways.

• Entamoeba histolytica Peroxiredoxin Activates Autophagy in M

  2026-05-28

  This study reveals that peroxiredoxin (Prx) from Entamoeba histolytica can trigger autophagy in macrophages through the TLR4-TRIF pathway, contributing to parasite-induced cytotoxicity. These findings clarify a novel pathogenic mechanism and provide a framework for dissecting host-pathogen interactions involving autophagy.

• SD 169 (indole-5-carboxamide): Precision p38 MAPK Inhibition

  2026-05-27

  SD 169 (indole-5-carboxamide) delivers dual-action, high-specificity inhibition of p38α/β MAPKs, empowering advanced research in inflammation, type 1 diabetes, and nerve regeneration. This guide translates bench-top breakthroughs into actionable protocols and troubleshooting strategies for reliable, reproducible outcomes.

• Anti-Inflammatory, Anti-Angiogenic Stent Reduces Tracheal Re

  2026-05-27

  Zhao et al. developed a dual-action airway stent integrating anti-inflammatory and anti-angiogenic agents to address tracheal in-stent restenosis. The study demonstrates that targeting both inflammation and vascularization can significantly mitigate granulation tissue hyperplasia, offering a promising strategy for durable airway stent function.

• TPPU as a Soluble Epoxide Hydrolase Inhibitor: Protocols & P

  2026-05-26

  TPPU is redefining experimental workflows for soluble epoxide hydrolase inhibition, enabling new rigor in studies of inflammatory pain and bone metabolism. This guide translates the latest Nrf2–osteoclastogenesis research into actionable protocols, troubleshooting strategies, and comparative insights for chronic inflammation and lipid signaling research.

• Dynasore: Precision Dynamin GTPase Inhibitor for Endocytosis

  2026-05-26

  Dynasore empowers researchers with reversible, high-fidelity inhibition of dynamin-dependent endocytosis, enabling detailed dissection of vesicle trafficking and signaling in cancer and microbiome-driven disease models. Its robust solubility and rapid, dose-dependent action make it a gold-standard tool for troubleshooting complex cellular workflows.

• Polyethylenimine Linear (PEI MW 40,000): Translational Lever

  2026-05-25

  This article explores the mechanistic foundations and strategic translational potential of Polyethylenimine Linear (PEI), MW 40,000 in DNA transfection. Integrating evidence from recent protocol optimization studies and comparative analyses, we provide actionable guidance and critical perspective for researchers aiming to scale transient gene expression and recombinant protein production from bench to bioreactor. The discussion synthesizes product intelligence, competitive context, and novel workflow recommendations, positioning APExBIO’s PEI MW 40,000 as a catalyst for innovation beyond standard product descriptions.

• SD 169 (Indole-5-carboxamide): Dual-Action p38 MAPK Inhibiti

  2026-05-25

  This article explores SD 169 (indole-5-carboxamide) as a next-generation, dual-action p38α/β MAPK inhibitor, blending mechanistic insights from recent kinase dephosphorylation studies with strategic guidance for translational researchers. We contextualize SD 169’s biological rationale, experimental validation, and translational impact, while distinguishing its advances from conventional inhibitors. Drawing on both peer-reviewed and workflow-focused literature, we provide actionable protocols and a forward-looking perspective for researchers tackling inflammation, neuroregeneration, and type 1 diabetes.

• Boc-D-FMK: Pan-Caspase Inhibitor for Apoptosis Research

  2026-05-24

  Boc-D-FMK is a cell-permeable, broad-spectrum pan-caspase inhibitor used in apoptosis research. It irreversibly inactivates caspases and is validated in both in vitro and in vivo inflammation models. Stringent handling protocols and context-aware application are essential for reproducibility.

• NF-κB/Apaf1/Caspase-9 Axis Drives Inflammation in Septic AKI

  2026-05-23

  This study uncovers the sequential activation of the NF-κB/Apaf1/caspase-9 signaling axis as a key driver of tubular inflammation and apoptosis in septic acute kidney injury. By elucidating the mechanistic suppression of autophagy and demonstrating the therapeutic potential of targeting this pathway, the research advances our understanding of septic AKI pathophysiology and points to new intervention strategies.

• 17-AAG (Tanespimycin): Precision HSP90 Inhibition in Oncolog

  2026-05-22

  17-AAG (Tanespimycin) is a synthetic HSP90 inhibitor with low-nanomolar potency in cancer models. It induces apoptosis by destabilizing oncogenic client proteins, disrupts MAPK signaling, and shows efficacy across multiple tumor types. The compound’s selectivity and solubility profile make it a preferred tool for HSP90 chaperone inhibition in cancer research.

• Coronavirus Macrodomain Counters PARP-Mediated Antiviral Res

  2026-05-22

  Grunewald et al. (2019) reveal that the coronavirus macrodomain is essential for evading host poly (ADP-ribose) polymerase (PARP)-mediated suppression of viral replication and for restricting interferon (IFN) expression. These findings clarify the interplay between viral macrodomains and host innate immunity, highlighting new avenues for antiviral research.

• Magneto-Piezoelectric Scaffolds Target JAK2-STAT3 in Bone Re

  2026-05-21

  Wu et al. report a multifunctional scaffold integrating magneto-piezoelectric nanoparticles, which disrupt bacterial biofilms and selectively activate oxidative phosphorylation in Icam1+ macrophages for infectious bone defect regeneration. By targeting the JAK2-STAT3 pathway, this approach offers a dual therapeutic strategy—controlling infection and promoting bone healing—with implications for advanced regenerative biomaterials.

• Toremifene: Precision Tool for Selective Estrogen-Receptor M

  2026-05-21

  Toremifene empowers researchers to dissect estrogen receptor signaling and calcium-driven metastatic pathways in hormone-responsive prostate cancer models. This guide delivers actionable workflows, troubleshooting insights, and translational strategies to leverage Toremifene’s potent, quantifiable activity in advanced experimental settings.

• TSPAN18 Protects STIM1 to Drive Bone Metastasis in Prostate

  2026-05-20

  Zhou et al. reveal that TSPAN18 promotes bone metastasis in prostate cancer by inhibiting TRIM32-mediated ubiquitination of STIM1, stabilizing STIM1 protein and activating calcium signaling. This mechanistic insight highlights TSPAN18 as a potential therapeutic target and provides new context for designing advanced hormone-responsive cancer research workflows.

16547 records 1/1104 page Next 12345 下5页 Last page